How Much Does ED Treatment Cost?

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·11 min read

"How much does ED treatment cost?" is one of the most common questions men ask before they ever sit down with a clinician — and the honest answer is that it depends almost entirely on which treatment is chosen. Erectile dysfunction is the most common sexual dysfunction in men, affecting more than half of men between 40 and 70, and it is highly treatable. But the available options span an enormous price range, from a few dollars for a generic tablet to several thousand dollars for a surgical implant. This guide lays out what actually drives those numbers, written to be useful both to patients comparing options and to providers thinking about how to offer and price these services.

This is clinical and business education, not medical advice and not a price quote. Costs vary by region, provider, formulation, and the specifics of any individual case, so the figures here are presented as honest ranges and the factors behind them — never as a guaranteed price.

What drives the cost of ED treatment

The single biggest factor in what ED treatment costs is the modality — the type of treatment itself. Erectile dysfunction has an unusually wide therapeutic ladder, and each rung carries a very different price structure. As Empire's faculty frames it for clinicians, treatment typically progresses from the least invasive and least expensive options toward more involved ones only as needed.

• Oral medications (PDE5 inhibitors). The first-line, lowest-cost option. Generic versions are inexpensive; brand-name versions cost considerably more.
• Injections and devices. Penile injection therapy and vacuum erection devices — mid-range, mostly cash-pay, with recurring supply costs for injectables.
• Shockwave therapy. An office-based, multi-session regenerative procedure — higher-cost, cash-pay, and still considered an emerging therapy.
• PRP (platelet-rich plasma). Another office-based regenerative procedure with a still-developing evidence base — higher-cost and cash-pay.
• Penile implants. A surgical solution reserved for men who have not responded to other treatments — the highest-cost option, but with very high reported satisfaction.

Beyond the modality itself, the other cost drivers are familiar: whether a product is generic or branded, whether a procedure is delivered once or as a series of sessions, the provider's time and expertise, geographic market, and — the big one — how much, if any, insurance absorbs. The sections below walk through each tier honestly.

Oral medications: generic vs brand

Oral PDE5 inhibitors are the first-line pharmacologic treatment for ED and, by a wide margin, the least expensive. They work by blocking the enzyme phosphodiesterase type 5, which preserves the signaling molecule (cyclic GMP) that relaxes penile blood vessels and supports blood flow during arousal. There are several FDA-approved agents in this class, and the cost difference between them is driven mostly by generic versus brand rather than by the drug itself.

The clearest example is sildenafil versus tadalafil — the generics of Viagra and Cialis. Sildenafil was the first PDE5 inhibitor approved for ED in 1998; since the brand lost exclusivity, generic sildenafil has become dramatically cheaper than brand-name Viagra while being the same molecule with the same mechanism. The same holds for tadalafil relative to brand Cialis. For most patients, the generic delivers the same clinical effect at a small fraction of the price, which is why generics dominate real-world prescribing.

Practically, this means oral therapy can be one of the most affordable medical treatments a patient encounters — sometimes only a few dollars per dose for generics — while the brand-name equivalents can cost many times more per tablet. Cost at this tier also depends on dose, quantity, pharmacy, and whether any insurance benefit applies. It is worth remembering the clinical caveat that applies regardless of price: these medications support blood flow but do not create desire. As Dr. Greenleaf puts it, without brain stimulation, "all the Viagra in the world will not function" — an important expectation to set so patients do not pay for a medication that was never going to address the actual problem.

Injections, shockwave, and PRP: the procedure tier

Above oral medications sit the office-based and device-based treatments. These are meaningfully more expensive than pills, and — importantly — they are almost entirely cash-pay. The cost reflects provider time, supplies and equipment, and, for the regenerative procedures, a multi-session treatment course rather than a one-time visit.

Penile injection therapy is highly effective, including in men who do not respond to oral medications. It uses agents such as alprostadil alone or compounded combinations (commonly Trimix or Quadmix). The recurring nature of injectable supplies and the fact that compounded formulations are filled by specialty pharmacies both factor into ongoing cost. Vacuum erection devices, by contrast, are among the more economical options — they are available without a prescription and over the counter — though they are a one-time purchase rather than a clinical service.

Shockwave therapy for ED is delivered as a series — clinical protocols commonly run several sessions, frequently in the range of four to twelve — using a device that emits high-energy acoustic waves to stimulate blood flow and tissue remodeling. Because it is multi-session, equipment-intensive, and not reimbursed, it lands well above oral therapy in cost. Patients should also know the evidence honestly: the Sexual Medicine Society of North America has recommended that shockwave therapy be used under research protocols, because more robust trial data are still needed. A reputable provider should disclose that the therapy is promising but still emerging.

PRP (platelet-rich plasma) for ED follows a similar pattern. It uses a concentrate from the patient's own blood, theorized to promote angiogenesis and tissue remodeling. The clinical evidence is mixed — some studies show improvement, while at least one randomized placebo-controlled trial found no significant difference versus placebo — and the overall quality of evidence remains limited. Like shockwave, it is a cash-pay, office-based procedure, and its price reflects provider expertise and supplies rather than insurance reimbursement.

Insurance vs cash-pay

This is where honesty matters most. In the men's-health and wellness-clinic setting where most of these services are offered, the great majority of ED treatment is cash-pay. Insurance behavior varies, but a realistic picture looks like this:

• Generic oral PDE5 inhibitors are the most likely to see some coverage — some plans cover a limited number of tablets per month — but many cover little or nothing for ED, and coverage is inconsistent.
• Injections and vacuum devices are sometimes partially covered, but frequently are not in elective wellness settings.
• Shockwave and PRP are essentially always cash-pay; as emerging therapies they are not reimbursed.
• Cosmetic-urology procedures — for example scrotal Botox or penile fillers — are not covered, as they are considered cosmetic. Scrotal Botox, for instance, is described in Empire's curriculum as typically running around $500 per session, with results lasting a few months and no insurance coverage.
• Surgical penile implants are the modality most likely to be covered when medically indicated, though this depends heavily on the plan.

The takeaway for patients is to verify benefits directly with their insurer and provider before assuming coverage. The takeaway for providers is structural: because most of this work is cash-pay, it sits outside the reimbursement squeeze that compresses margins elsewhere in medicine — which is precisely why so many practices are adding it.

Why the numbers vary so much

It would be easy — and misleading — to publish a single price for "ED treatment." We deliberately do not, because the real cost is a function of several variables that differ from patient to patient and practice to practice:

• The modality chosen — the dominant factor, spanning inexpensive generics to surgical implants.
• Generic vs brand for medications, often a difference of many multiples.
• Single treatment vs a multi-session series for shockwave and PRP.
• Geography and local market, which shift cash-pay pricing considerably.
• Provider expertise and setting, from a primary-care prescription to a specialized men's-health clinic.
• Insurance involvement, which is partial at best for pills and generally absent for procedures.
• Whether the problem is actually being addressed. ED can be the "canary in the coal mine" for cardiovascular disease, and low desire often traces back to stress and other root causes that no pill resolves. Money spent on the wrong target is money wasted — appropriate evaluation is itself a cost factor worth respecting.

Any provider or page that quotes a precise, universal price for ED treatment should be viewed with some skepticism. The credible answer is a range tied to the specific plan of care.

The provider side: a high-demand cash-pay service line

For clinicians, the cost conversation has a second half: men's sexual health is one of the more attractive cash-pay service lines a practice can add, and understanding why is part of running it well. The demand is real and growing. The U.S. sexual wellness market was valued in the billions and is projected to keep expanding at a healthy compound annual growth rate — a reflection of rising awareness and an aging population, against a backdrop of significant under-treatment, since sexual dysfunction is widely considered underreported due to stigma.

From a business standpoint, the appeal is straightforward and worth stating honestly. These services are largely paid out of pocket, which means they sidestep insurance reimbursement and the administrative drag that comes with it. Many of the higher-value offerings — shockwave, PRP, injection programs, cosmetic-urology procedures, and the topical and device products that can be sold from the office — are delivered as packages or series, which supports predictable, recurring revenue. And they extend naturally from adjacent work in hormone optimization and anti-aging, where many of the same patients are already being seen. For a practice already treating low testosterone or offering peptides such as PT-141 for libido, sexual health is a logical, high-demand extension rather than a cold start.

None of that means it is easy money. Pricing has to be defensible and transparent; the emerging therapies have to be presented with honest evidence; and patient selection, consent, and clinical competence still govern outcomes. The economics are favorable, but only when the medicine is done properly — which is exactly why structured training matters before a practice builds out this line. For the operational how-to, see how to add sexual health to your practice.

Pricing and building the service line, taught properly

Knowing the cost tiers is one thing; building a compliant, profitable, clinically sound sexual health service is another. That is the gap Empire's training is designed to close. The course teaches the full therapeutic ladder — oral agents, injections and devices, shockwave, PRP, implants, and cosmetic urology — alongside the practical business architecture: how to structure pricing for cash-pay services, how to bundle multi-session therapies, and how to present emerging treatments to patients with appropriate, evidence-honest expectations.

The clinical depth here — mechanisms, patient selection, procedure technique, and pricing strategy — is taught in Empire's course rather than reproduced on this page. The summary table below is a high-level map of the cost tiers; the detailed protocols, sourcing, and fee-setting frameworks live in the training.